Treatment of HER2+ Breast Cancer: Kanjinti, a biosimilar to trastuzumab
By Kaye
Kaye
Kaye obtained her Masters of Pharmacy degree from the University College London and has spent the better part of her career as a clinical pharmacist in a tertiary care hospital. Her professional interests are centred on HEOR and HTA work, in hopes of ultimately influencing cost-effective decisions for patient care.
Copyright © Medical Channel Asia 2024.
All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.